Kintara Therapeutics to be Acquired by DelMar Pharmaceuticals

TL;DR

Kintara is getting bought by DelMar, deal expected Q4 2024.

AI Summary

Kintara Therapeutics, Inc. announced on July 3, 2024, that it has entered into a definitive agreement to be acquired by DelMar Pharmaceuticals, Inc. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions. This acquisition will combine two companies focused on developing novel cancer therapies.

Why It Matters

This acquisition signifies a consolidation in the oncology therapeutics space, potentially impacting the development and availability of Kintara's pipeline drugs.

Risk Assessment

Risk Level: medium — The acquisition is subject to closing conditions, and the success of the combined entity's pipeline drugs remains uncertain.

Key Players & Entities

• Kintara Therapeutics, Inc. (company) — Registrant
• DelMar Pharmaceuticals, Inc. (company) — Acquiring company
• July 3, 2024 (date) — Date of agreement
• Fourth quarter of 2024 (date) — Expected closing date

FAQ

Key Financial Figures

• $5.0 m — f the Agreement, TuHURA will pay Kineta $5.0 million, with $2.5 million paid at signin
• $2.5 million — HURA will pay Kineta $5.0 million, with $2.5 million paid at signing and, subject to certain
• $150,000 — arties), TuHURA shall pay an additional $150,000 as an additional Exclusivity Payment, i
• $300,000 — ity Payment, in an amount not to exceed $300,000 for the two (2) available Renewal Perio
• $5.0 million — unction with the Agreement, TuHURA sold $5.0 million of shares of its common stock in a priv

Filing Documents

• ktra-20240703.htm (8-K) — 88KB
• ktra-ex99_1.htm (EX-99.1) — 45KB
• img40499469_0.jpg (GRAPHIC) — 88KB
• img40499469_1.jpg (GRAPHIC) — 5KB
• 0000950170-24-081937.txt ( ) — 399KB
• ktra-20240703.xsd (EX-101.SCH) — 30KB
• ktra-20240703_htm.xml (XML) — 5KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On July 8, 2024, Kintara Therapeutics, Inc. (" Kintara ") and TuHURA Biosciences, Inc. (" TuHURA ") issued a press release announcing that TuHURA has entered into an Exclusivity and Right of First Offer Agreement (the " Agreement ") with Kineta, Inc. (Nasdaq: KA) (" Kineta ") for the potential acquisition of Kineta's KVA12123 anti-VISTA antibody and related rights and assets associated with and derived from the asset. The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission (the " SEC "), and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

01. Other Events

Item 8.01. Other Events. On July 8, 2024, Kintara and TuHURA announced that TuHURA entered into the Agreement with Kineta for the potential acquisition of Kineta's KVA12123 anti-VISTA antibody and related rights and assets associated with and derived from the asset. Capitalized terms used but not otherwise defined herein shall have the meaning ascribed to them in the Agreement. KVA12123 is a rationally targeted, anti-VISTA antibody checkpoint inhibitor designed to reverse VISTA immune suppression and remodel the tumor microenvironment (TME) to overcome acquired resistance to immunotherapies. To date, KVA12123 has demonstrated a favorable clinical safety and tolerability profile observed with no dose limiting toxicities and no evidence of cytokine release syndrome (CRS) associated toxicities at the doses examined. Pursuant to the Agreement, among other things, Kineta has granted TuHURA an exclusive right to acquire Kineta's worldwide patents, patent rights, patent applications, product and development program assets, technical and business information, and other rights and assets associated with and derived from its development program related to KVA12123, Kinteta's VISTA blocking immunotherapy, during the period commencing as of July 3, 2024 (the " Effective Date ") and continuing through the first to occur of (a) the execution of any Definitive Agreement with respect to a Potential Transaction by TuHURA or one or more of its affiliates and (b) 11:59 PM Eastern Time on October 1, 2024, subject to extension as noted in the following sentence (the " Exclusivity Period "). In the event that the Parties are engaged in good faith discussions regarding a Potential Transaction on the date on which the Exclusivity Period (or any renewal thereof) is scheduled to expire and TuHURA has not yet closed the transactions contemplated by that previously announced agreement and plan of merger (the " Merger Agreement ") by and among TuHURA, Kintara and Kayak Mergeco, Inc., a wh

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K and the press release attached hereto as Exhibit 99.1 contain forward-looking statements based upon Kintara's and TuHURA's current expectations. This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by terminology such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "should," "would," "project," "plan," "expect," "goal," "seek," "future," "likely" or the negative or plural of these words or similar expressions. These statements are only predictions. Kintara and TuHURA have based these forward-looking statements largely on their then-current expectations and projections about future events, as well as the beliefs and assumptions of management. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond each of Kintara's and TuHURA's control, and actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: (i) the risk that the conditions to the closing or consummation of the proposed Merger are not satisfied, including the failure to obtain stockholder approval for the proposed Merger; (ii) uncertainties as to the timing of the consummation of the proposed Merger and the ability of each of Kintara and TuHURA to consummate the transactions contemplated by the proposed Merger; (iii) risks related to Kintara's and TuHURA's ability to correctly estimate their respective operating expenses and expenses associated with the proposed Merger, as applicable, as well as uncertainties regarding the impact any delay in the closing would have on the anticipated cash resources of the resulting combined company upon closing and other events and unanticipated spending and costs that could reduc

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Press release of Kintara Therapeutics, Inc. and TuHURA Biosciences, Inc. issued July 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KINTARA THERAPEUTICS, INC. Date: July 8, 2024 By: /s/ Robert E. Hoffman Name: Robert E. Hoffman Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR